home / stock / fgen / fgen quote
Last: | $0.691 |
---|---|
Change Percent: | -7.0% |
Open: | $0.745 |
Close: | $0.743 |
High: | $0.75 |
Low: | $0.6801 |
Volume: | 2,506,300 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.691 | $0.745 | $0.743 | $0.75 | $0.6801 | 2,506,300 | 07-03-2024 |
$0.743 | $0.7778 | $0.743 | $0.791 | $0.7318 | 3,588,499 | 07-02-2024 |
$0.7701 | $0.9011 | $0.7701 | $0.913 | $0.76 | 4,798,241 | 07-01-2024 |
$0.8923 | $1 | $0.8923 | $1.046 | $0.8923 | 15,176,469 | 06-28-2024 |
$1.03 | $1.07 | $1.03 | $1.07 | $1.01 | 1,421,634 | 06-27-2024 |
$1.055 | $1.17 | $1.055 | $1.17 | $1.0401 | 1,569,468 | 06-26-2024 |
$1.17 | $1.2 | $1.17 | $1.2 | $1.15 | 923,543 | 06-25-2024 |
$1.2 | $1.14 | $1.2 | $1.21 | $1.12 | 1,093,548 | 06-24-2024 |
$1.13 | $1.1 | $1.13 | $1.19 | $1.1 | 1,341,495 | 06-21-2024 |
$1.1 | $1.04 | $1.1 | $1.13 | $1.01 | 1,352,874 | 06-20-2024 |
$1.03 | $1.08 | $1.03 | $1.08 | $1.03 | 972,435 | 06-19-2024 |
$1.03 | $1.08 | $1.03 | $1.08 | $1.03 | 972,435 | 06-18-2024 |
$1.06 | $1.12 | $1.06 | $1.12 | $1.06 | 1,037,214 | 06-17-2024 |
$1.12 | $1.18 | $1.12 | $1.18 | $1.1 | 991,666 | 06-14-2024 |
$1.16 | $1.15 | $1.16 | $1.19 | $1.11 | 1,188,621 | 06-13-2024 |
$1.16 | $1.15 | $1.16 | $1.2 | $1.135 | 1,360,282 | 06-12-2024 |
$1.13 | $1.12 | $1.13 | $1.14 | $1.08 | 662,957 | 06-11-2024 |
$1.13 | $1.07 | $1.13 | $1.17 | $1.05 | 1,328,245 | 06-10-2024 |
$1.1 | $1.15 | $1.1 | $1.18 | $1.1 | 1,940,398 | 06-07-2024 |
$1.19 | $1.19 | $1.19 | $1.21 | $1.13 | 1,940,803 | 06-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To register, click here . The event will feature Rahul Aggarwal, M.D. (Uni...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO ® in patients with select solid tumors FibroGen to evaluate FG-3175, an anti-c-c motif chemokine receptor 8 (CCR8) mAb, a...